Novelix Pharmaceuticals
- Market cap
- ₹ 166 Cr.
- P/E
- 63.3x
- P/B
- 2.85x
- 52-week range
- 47.33 – 92
- ROE
- 8%
- ROCE
- 10%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Healthcare Services
- Industry
- Healthcare Research, Analytics & Technology
- Listed on
- BSE
About
Novelix Pharmaceuticals Ltd, formerly Trimurthi Limited, is an India-based company, which is engaged in the business of trading pharmaceuticals and related products and is in the business of trading shares and securities. The Company's segments include Pharma Business, Investment is Shares, Trading in shares, Foods, and Finance.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Research, Analytics & Technology: 11 companies →Novelix Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)63.3 against a typical 34.7: pricier than most peers (1st = cheapest).10th of 11
- Sales growth+65.1% against a typical +16.4% from a year earlier.3rd of 10
- Profit growth+972.7% against a typical 0% from a year earlier.1st of 5
- Share price, 3 months−11.4% against a typical −11.4%.6th of 11
- Size₹ 166.3 Cr. market value against a typical ₹ 197.8 Cr. (1st = largest).7th of 11
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 1 | 1 | 1 | 4 | 5 | 21 | 22 | 36 | 48 | 25 | 37 |
| Expenses | 1 | 1 | 1 | 1 | 4 | 5 | 21 | 22 | 36 | 47 | 24 | 36 |
| Operating Profit | −0 | −0 | 0 | −0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| OPM % | −11.8% | −22% | 17.9% | −73.3% | 5.6% | 2.5% | 1.1% | 0.8% | 1.9% | 2.7% | 5.1% | 3.6% |
| Other Income | 0 | 0 | 0 | 0 | −0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −0 | −0 | 0 | −0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Tax % | 0% | 0% | 0% | 2.9% | 0% | −15.4% | 14.3% | 41.2% | 26.4% | 21.9% | 26% | −5.4% |
| Net Profit | −0 | −0 | 0 | −0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| EPS in Rs | −0.09 | −0.04 | 0.35 | −0.35 | 0.13 | 0.15 | 0.18 | 0.09 | 0.37 | 0.58 | 0.43 | 0.49 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 63%
- 5 Years
- 152%
- 3 Years
- 310%
- TTM
- 180%
- 10 Years
- 40%
- 5 Years
- 23%
- 3 Years
- 255%
- TTM
- 535%
- 10 Years
- 29%
- 5 Years
- 60%
- 3 Years
- 104%
- TTM
- —
- 10 Years
- −1%
- 5 Years
- 2%
- 3 Years
- 5%
- TTM
- —
Peers
Listed companies in the same business.
| Novelix Pharmaceuticals | ₹ 61.15 | ₹ 166 Cr. | 63.3x | 2.9x | 8% | — |
| MedPlus Health Services | ₹ 597.45 | ₹ 7,182 Cr. | 43.7x | 4.9x | 11.8% | 3.2% |
| Muller & Phipps India Ltd | ₹ 195.00 | ₹ 12 Cr. | — | — | — | −0.9% |
Management
- Arun Kumar Bhangadia
- Chairman of the Board, Managing Director
- Bhoomika Choudhary
- Chief Financial Officer
- Nishita Kalantri
- Compliance Officer, Company Secretary
- Venkateshwarlu Pulluru
- Whole-time director
Prices are delayed and for information only. Nothing on this page is investment advice.